Research Analysts Offer Predictions for BioNTech Q1 Earnings

BioNTech SE (NASDAQ:BNTX - Free Report) - HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of BioNTech in a note issued to investors on Thursday, June 5th. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($2.31) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $145.00 target price on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech's Q2 2026 earnings at ($2.33) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at $0.90 EPS and FY2026 earnings at ($4.46) EPS.

Other analysts have also recently issued reports about the stock. Morgan Stanley decreased their price target on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 6th. Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. Citigroup restated a "buy" rating and set a $140.00 target price (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. BMO Capital Markets upped their price target on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. Finally, Truist Financial reiterated a "buy" rating and issued a $155.00 price objective (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $138.25.

BioNTech Price Performance

NASDAQ:BNTX traded down $0.54 during mid-day trading on Monday, reaching $104.92. 1,523,808 shares of the company were exchanged, compared to its average volume of 944,500. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a market cap of $25.22 billion, a PE ratio of -49.96 and a beta of 1.29. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a fifty day moving average of $100.22 and a 200 day moving average of $108.34.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the previous year, the firm earned $1.90 earnings per share. The business's revenue was down 19.5% on a year-over-year basis.

Institutional Investors Weigh In On BioNTech

Hedge funds have recently bought and sold shares of the company. Van ECK Associates Corp lifted its holdings in BioNTech by 25.1% during the fourth quarter. Van ECK Associates Corp now owns 118,418 shares of the company's stock worth $13,493,000 after acquiring an additional 23,733 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of BioNTech during the 4th quarter valued at about $1,118,000. Vontobel Holding Ltd. grew its position in shares of BioNTech by 24.6% in the 4th quarter. Vontobel Holding Ltd. now owns 21,385 shares of the company's stock valued at $2,437,000 after purchasing an additional 4,227 shares during the period. AlphaCentric Advisors LLC bought a new stake in BioNTech during the 4th quarter worth approximately $168,000. Finally, Flossbach Von Storch SE raised its holdings in BioNTech by 1.1% during the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock worth $502,160,000 after buying an additional 47,236 shares during the period. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.